Gene therapy is a medical technique that treats disease by modifying a person’s genes rather than managing symptoms with ongoing medication. Instead of taking a drug every day for years, gene therapy aims to fix or work around the genetic root of a problem, often with a single treatment. The FDA has approved dozens of gene therapy products, and nearly 2,000 clinical trials were active globally as of 2024, with the majority targeting cancer and rare diseases.
How Gene Therapy Works
At its core, gene therapy delivers new or modified genetic material into your cells to change how they function. The specific goal depends on the disease being treated, but it generally falls into one of three categories.
Gene addition puts a working copy of a gene into cells that have a broken or missing version. Your cells then use the new copy to produce the protein they couldn’t make before. This is the most common approach for inherited diseases where a single gene is faulty.
Gene silencing switches off a gene that’s causing harm. In sickle cell disease, for example, one treatment silences a gene that blocks production of a healthy form of hemoglobin. With that blocker removed, the body resumes making hemoglobin that doesn’t cause sickling.
Gene correction directly fixes the mutation in your DNA so the gene works normally again. This is the most precise approach and has become more feasible with newer editing tools like CRISPR.
Getting Genetic Material Into Your Cells
The biggest engineering challenge in gene therapy is delivery. DNA doesn’t just walk into a cell on its own. It needs a carrier, called a vector, to get past the cell membrane and into the right place. Most approved gene therapies use modified viruses as vectors. These viruses have been stripped of their ability to cause disease but retain their natural talent for entering human cells and depositing genetic cargo.
Two viral vectors dominate the field. Adeno-associated virus (AAV) vectors deliver DNA that stays in the cell nucleus without inserting into the cell’s own chromosomes. This makes AAV relatively safe, and the delivered gene can keep working for months or longer, especially in cells that don’t divide frequently, like nerve and heart cells. Lentiviral vectors take a different approach: they insert the new gene directly into the cell’s DNA, which provides more durable, long-term expression. This is particularly useful for children, whose cells are still actively dividing. The tradeoff is a small risk that the insertion lands in the wrong spot and disrupts a gene that shouldn’t be disrupted.
In Vivo vs. Ex Vivo Delivery
Gene therapy reaches your cells through two broad routes. In vivo therapy delivers the vector directly into your body, typically through an injection or infusion that targets a specific organ. This is the approach used when the cells that need fixing are deep inside tissues you can’t easily remove, like the liver, eye, or brain.
Ex vivo therapy works differently. Doctors first remove cells from your body, modify them in a lab, and then return the corrected cells. This is the standard method for blood-related diseases and many cancer treatments, because blood and immune cells can be extracted, engineered, and reinfused relatively straightforwardly.
CRISPR and the Shift to Gene Editing
Traditional gene therapy mostly adds new genes without altering the existing DNA. CRISPR-Cas9, a tool adapted from a bacterial immune system, changed the game by allowing scientists to cut DNA at a precise location and either delete, repair, or replace specific sequences. It works by pairing a guide molecule (made of RNA) with a protein that acts like molecular scissors, creating a targeted break in the DNA strand. The cell’s own repair machinery then fixes the break, either disabling the gene or incorporating a corrected version.
CRISPR’s precision and relatively low cost have opened the door to treating diseases that were previously considered untouchable. The first CRISPR-based therapy, approved in late 2023 for sickle cell disease, uses ex vivo editing to modify a patient’s own stem cells. Researchers are now working on in vivo CRISPR therapies that could edit genes inside the body without needing to remove cells first.
What CAR-T Therapy Looks Like for Patients
One of the most visible forms of gene-modified cell therapy is CAR-T, used to treat certain blood cancers. It offers a concrete picture of what the gene therapy process involves from a patient’s perspective. The entire process takes roughly three months from initial evaluation to the end of the post-infusion observation period.
It starts with about a week of eligibility testing, followed by insurance approval, which typically takes two to four weeks. Then doctors collect immune cells from your blood through a process called apheresis, which requires two hospital visits. Those cells are shipped to a lab, where they’re genetically reprogrammed to recognize and attack cancer cells. This engineering step takes about three weeks.
Before the modified cells are infused back into your body, you undergo five days of chemotherapy to suppress your existing immune system and give the new cells room to expand. The actual infusion is surprisingly quick, often 15 minutes to an hour. After that, you’re monitored for 30 days for side effects, including a potentially serious inflammatory reaction as the engineered cells activate. Follow-up visits continue every two to three months, and most patients take anti-infection medication for a full year because the treatment weakens the natural immune system.
Risks and Safety Concerns
Gene therapy’s power to permanently alter cells is also the source of its biggest risks. Insertional mutagenesis occurs when a viral vector inserts its genetic cargo near a gene that controls cell growth, potentially switching it on and triggering cancer. Early gene therapy trials in the 2000s saw several patients develop leukemia for exactly this reason, and the risk remains a concern with lentiviral vectors that integrate into the genome.
CRISPR and other editing tools carry a different risk: off-target effects. The molecular scissors can occasionally cut at unintended sites in the genome, leading to unwanted gene disruption, chromosomal rearrangements, or loss of genetic material. Improving the accuracy of guide molecules is one of the most active areas of research.
Immune reactions are another challenge. Your body can recognize viral vectors as foreign invaders and mount an immune response that destroys them before they deliver their payload, or that causes dangerous inflammation. For CAR-T therapy specifically, the rapid activation of engineered immune cells can trigger a severe inflammatory response that requires careful management.
Cost and Access
Gene therapies are among the most expensive medical treatments ever created. The one-time spinal muscular atrophy treatment for infants carries an upfront price of $2.125 million, and a gene therapy for hemophilia A was projected at around $2 to $2.5 million. These numbers cause sticker shock, but they exist in context: the lifetime cost of standard treatment for severe hemophilia A, with regular infusions of clotting factor, has been estimated between $15 million and $100 million.
The economic argument for gene therapy hinges on its one-time nature. If a single treatment replaces decades of ongoing medication, the total cost to the healthcare system may actually be lower. But the upfront price creates real barriers. Insurance approval can be slow and uncertain, and the treatments are only available at specialized medical centers, which limits access for patients in rural areas or lower-income countries.
The Ethical Line: Somatic vs. Germline
All currently approved gene therapies modify somatic cells, meaning the changes affect only the treated patient and cannot be passed to their children. Germline editing, which would alter eggs, sperm, or embryos and create heritable changes, is a fundamentally different proposition. Around 40 countries have discouraged or banned germline editing research, including 15 in Western Europe.
The scientific community broadly agrees that germline editing for reproductive purposes should not be attempted until it can be proven safe. An international effort led by the U.S., U.K., and China launched in 2015 to coordinate regulation of genome editing technologies. The core concern is straightforward: mistakes in somatic gene therapy affect one person, but mistakes in germline editing would ripple through generations with no way to recall them.
Where Gene Therapy Stands Now
The FDA’s list of approved cellular and gene therapy products now includes nearly 50 entries, spanning treatments for blood cancers, inherited blindness, spinal muscular atrophy, sickle cell disease, hemophilia, and several other conditions. Of the roughly 1,975 clinical trials underway globally, 56.6% target cancer and 35.4% focus on rare diseases. The field has moved well past the proof-of-concept stage into routine, if still expensive, clinical use for a growing number of conditions that previously had no effective treatment.